Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 17;9(11):3692.
doi: 10.3390/jcm9113692.

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation

Matteo Dragani  1 , Giovanna Rege Cambrin  1 , Paola Berchialla  1 , Irene Dogliotti  2 , Gianantonio Rosti  3 , Fausto Castagnetti  3 , Isabella Capodanno  4 , Bruno Martino  5 , Marco Cerrano  2 , Dario Ferrero  2 , Carlo Gambacorti-Passerini  6 , Monica Crugnola  7 , Chiara Elena  8 , Massimo Breccia  9 , Alessandra Iurlo  10 , Daniele Cattaneo  10 , Sara Galimberti  11 , Antonella Gozzini  12 , Monica Bocchia  13 , Francesca Lunghi  14 , Michele Cedrone  15 , Nicola Sgherza  16 , Luigia Luciano  17 , Sabina Russo  18 , Marco Santoro  19 , Valentina Giai  20 , Giovanni Caocci  21 , Luciano Levato  22 , Elisabetta Abruzzese  23 , Federica Sora  24 , Giuseppe Saglio  1 , Carmen Fava  1
Affiliations

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation

Matteo Dragani et al. J Clin Med. .

Abstract

Successful discontinuation of tyrosine kinase inhibitors has been achieved in patients with chronic-phase chronic myeloid leukemia (CML). Careful molecular monitoring after discontinuation warrants safe and prompt resumption of therapy. We retrospectively evaluated how molecular monitoring has been conducted in Italy in a cohort of patients who discontinued tyrosine kinase inhibitor (TKI) treatment per clinical practice. The outcome of these patients has recently been reported-281 chronic-phase CML patients were included in this subanalysis. Median follow-up since discontinuation was 2 years. Overall, 2203 analyses were performed, 17.9% in the first three months and 38.4% in the first six months. Eighty-six patients lost major molecular response (MMR) in a mean time of 5.7 months-65 pts (75.6%) during the first six months. We evaluated the number of patients who would experience a delay in diagnosis of MMR loss if a three-month monitoring schedule was adopted. In the first 6 months, 19 pts (29.2%) would have a one-month delay, 26 (40%) a 2-month delay. Very few patients would experience a delay in the following months. A less intense frequency of monitoring, particularly after the first 6 months off treatment, would not have affected the success of treatment-free remission (TFR) nor put patients at risk of progression.

Keywords: chronic myeloid leukemia; molecular monitoring; treatment-free remission.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Percentage of patients who had a minimal residual disease assessment during the first 12 months in our retrospective cohort.
Figure 2
Figure 2
Delay of MMR (major molecular response) loss detection by timeframe if 3-month monitoring schedule is applied in our cohort.
See this image and copyright information in PMC

References

    1. Etienne G., Guilhot J., Rea D., Rigal-Huguet F., Nicolini F., Charbonnier A., Guerci-Bresler A., Legros L., Varet B., Gardembas M., et al. Long-Term Follow-up of the French Stop Imatinib (STIM1) Study in Patients with Chronic Myeloid Leukemia. J. Clin. Oncol. 2017;35:298–305. doi: 10.1200/JCO.2016.68.2914. - DOI - PubMed
    1. Campiotti L., Suter M.B., Guasti L., Piazza R., Gambacorti-Passerini C., Grandi A.M., Squizzato A. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis. Eur. J. Cancer. 2017;77:48–56. doi: 10.1016/j.ejca.2017.02.028. - DOI - PubMed
    1. Fava C., Rege-Cambrin G., Dogliotti I., Cerrano M., Berchialla P., Dragani M., Rosti G., Castagnetti F., Gugliotta G., Martino B., et al. Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica. 2019;104:1589–1596. doi: 10.3324/haematol.2018.205054. - DOI - PMC - PubMed
    1. Saussele S., Richter J., Guilhot J., Gruber F.X., Hjorth-Hansen H., Almeida A., Mjanssen J.J.W., Mayer J., Koskenvesa P., Panayiotidis P., et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747–757. doi: 10.1016/S1470-2045(18)30192-X. - DOI - PubMed
    1. Rea D., Nicolini F.E., Tulliez M., Guilhot F., Guilhot J., Guerci-Bresler A., Gardembas M., Coiteux V., Guillerm G., Legros L., et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: Interim analysis of the STOP 2G-TKI study. Blood. 2017;129:846–854. doi: 10.1182/blood-2016-09-742205. - DOI - PubMed